Skip to main content

CheckMate 227 trial

This multi-part phase III trial of patients with treatment-naïve, stage IV or recurrent non-small-cell lung cancer (NSCLC) has previously shown a progression-free survival benefit with nivolumab plus ipilimumab versus chemotherapy in the subgroup with a high tumor mutational burden.

The final analysis of part 1 was presented at the ESMO Congress 2019 and demonstrated that nivolumab plus low-dose ipilimumab is a viable non-chemotherapy option for first-line treatment of advanced NSCLC.

Solange Peters discusses the implications of the CheckMate 227 findings and outlines the key next steps (3:45):

Read the transcript

Receive all the latest conference coverage straight to your inbox

Back to the WCLC 2019 conference hub